Skip to content
Screener

Niagen Bioscience NAGE Q1 2026 earnings

Reported May 6, 2026 · After market close

Revenue$31.5MBeat by $444.0K
EPS$0.07Beat by $0.01
Revenue estimate$31.0M
EPS estimate$0.06

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$34.4M
EPS estimate$0.01

Financials

Q1 2026

Income statement

See full
Revenue$31.5M+3.3%
Gross profit$20.0M+3.3%
Operating income$1.6M-67.0%
Net income$6.3M+24.8%
EPS (diluted)$0.07+16.7%

Balance sheet

See full
Cash & equivalents$66.5M+19.7%
Total debt$2.6M-26.9%
Total equity$82.3M+48.8%
Total assets$114.3M+40.6%

Cash flow

See full
Operating cash flow-$1.2M-115%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$353.15M—
Enterprise value$289.18M—
P/E18.9×—
P/S2.7×—

Profitability

See full
Gross margin64.3%+1.8pp
Operating margin10%-2.2pp
Net margin14.3%+1.2pp

Returns & leverage

See full
Return on equity27.1%-6.4pp
Debt / equity0×0.0×
Current ratio4.6×+0.9×

Segments

By segment

See full
Consumer Products segment$22.4M+4.2%
Ingredients segment$8.6M+4.8%
Analytical Reference Standards and Services segment$423.0K-47.8%
Corporate and other$74.0K—

FAQ

When did Niagen Bioscience report Q1 2026 earnings?
Niagen Bioscience (NAGE) reported Q1 2026 earnings on May 6, 2026 after market close.
What were Niagen Bioscience's Q1 2026 revenue and EPS?
Niagen Bioscience reported revenue of $31.5M and eps of $0.07 for Q1 2026.
Did Niagen Bioscience beat estimates in Q1 2026?
Revenue beat the consensus estimate of $31.0M by $444.0K. EPS beat the consensus estimate of $0.06 by $0.01.
How did Niagen Bioscience's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.3% from $30.5M a year earlier and eps grew 75.0% from $0.04.
Where can I find Niagen Bioscience's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001386570-26-000031) and the 10-Q periodic report (0001386570-26-000030) directly on SEC EDGAR. The filing index links above go to sec.gov.